OS Therapies Inc
OSTX
Analytical Summary
On an absolute basis, OS Therapies Inc shows solid but mixed fundamentals, with Return on Invested Capital holding up well. Watch FCF / Net Income against typical quality thresholds. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.
4-Year Financial Trajectory
Annualinfo Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.
Bullish Indicators
- Return on Invested CapitalReturn on Invested Capital of 372.0% is excellent on an absolute basis (target > 10%)
Bearish Risks
- FCF / Net IncomeFCF / Net Income of 0.50x is weak on an absolute basis (target > 1x)
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Mar 7, 2024 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| EPS Growth YoY (%) |
-11.4%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
39.7%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-223.7%
Weak
Weak
Year-over-year change in net income |
-14.0%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) | — |
-6.2%
Weak
Weak
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Mar 7, 2024 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| FCF / Net Income (x) |
0.50x
Weak
↓
Weak
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.82x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.39x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Mar 7, 2024 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
372.0%
Excellent
↑
Excellent
Improving
Return earned on debt + equity capital invested
Optimal:
> 10%
|
102.8%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
14.3%
Good
Good
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-419.7%
Weak
↓
Weak
Declining
Operating profit relative to total assets
Optimal:
> 10%
|
-123.0%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-544.1%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) | — |
169.6%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+1030%)
|
32.4%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+116%)
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Mar 7, 2024 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Debt to Equity (x) | — | — |
-0.00x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-101%)
|
— |
| Net Debt (USD) | — | — | $100.00K | — |
| Debt / EBITDA (x) | — | — |
-0.02x
Excellent
Excellent
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
— |
Secondary lens
Benchmark Lens
Benchmarks are disabled until comparison data is defensible.
Unavailable
Benchmark Lens
Benchmarks are disabled until comparison data is defensible.
Benchmarks unavailable
Verdicts use absolute quality thresholds, not peer comparison — only 0 comparable companies are currently available for ranking.
Use Statement Evidence firstCompare OSTX with peers
Stack OSTX against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 14 quarters